dengue pipeline insight

DelveInsight’s, “Dengue  Pipeline Insight 2026” report provides comprehensive insights about 15+ companies and 20+ pipeline drugs in Dengue pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

• • Global coverage

Dengue Disease Understanding

Dengue Overview

Dengue is a major mosquito-borne viral disease caused by a single-stranded RNA virus transmitted primarily by Aedes aegypti and Aedes albopictus mosquitoes. Endemic in over 140 countries across Asia, Africa, the Americas, and the Eastern Mediterranean, dengue places more than 2.5 billion people at risk, particularly children in tropical and subtropical regions. Approximately 100 million symptomatic infections occur annually, with nearly 75% reported in Asia and the Western Pacific. Rapid urbanization, population growth, poor sanitation, increased travel, and the widespread distribution of mosquito vectors have significantly contributed to the global rise and expansion of dengue outbreaks over recent decades. Hyperendemic transmission, especially in South and Southeast Asia, has led to increased hospitalization and mortality, with recent shifts showing rising infection rates among adolescents and adults. Additionally, dengue has emerged as a growing concern among international travelers, often surpassing malaria in frequency among those returning from Asia. As vector control measures alone have shown limited success, integrated strategies involving effective vaccination, public awareness, surveillance, and personal protection against mosquito bites are essential to reduce transmission and prevent further geographic spread of the disease. 

Dengue virus, a single-stranded RNA virus of the Flavivirus genus, is transmitted mainly by Aedes aegypti and Aedes albopictus mosquitoes and exists in four serotypes (DEN-1 to DEN-4). Common in tropical and subtropical regions, dengue ranges from asymptomatic infection to severe forms such as dengue hemorrhagic fever (DHF) and dengue shock syndrome (DSS), characterized by plasma leakage, thrombocytopenia, bleeding, and organ failure. Secondary infection with a different serotype significantly increases the risk of severe disease through antibody-dependent enhancement (ADE), which promotes viral replication and excessive immune responses. Factors such as inflammatory cytokines, complement activation, viral genetics, and host immunity further influence disease severity and clinical outcomes.

Dengue infection should be suspected in individuals from endemic or epidemic regions presenting with acute fever, myalgia, headache, nausea, rash, and body pain without clear respiratory or organ-specific symptoms. The disease ranges from mild dengue fever (DF) to severe dengue characterized by plasma leakage, hemorrhage, shock, and multi-organ failure. Severe forms such as dengue hemorrhagic fever (DHF) and dengue shock syndrome (DSS) are associated with thrombocytopenia, hemoconcentration, vascular leakage, and circulatory collapse, with children more prone to plasma leakage and adults more likely to develop severe bleeding and liver dysfunction. Early diagnosis, recognition of warning signs, and prompt supportive management significantly reduce mortality. Common complications include hemorrhage, hepatic impairment, neurological manifestations, renal failure, cardiac involvement, and respiratory distress, while comorbidities and secondary infections further worsen outcomes, especially in adults, elderly patients, and pregnant women. Despite potential severity, most patients recover completely with timely fluid management and intensive supportive care.

Clinical differentiation of dengue from other acute febrile illnesses is challenging, though laboratory findings such as leukopenia, thrombocytopenia, and mildly elevated AST levels may support diagnosis. Early and accurate detection is crucial for timely supportive care, fluid management, and monitoring of severe complications such as plasma leakage, bleeding, and organ dysfunction. While the WHO-recommended tourniquet test has limited sensitivity and specificity, definitive diagnosis relies on laboratory methods including RT-PCR and NS1 antigen detection during the early phase of illness, and IgM/IgG antibody detection in later stages. RT-PCR remains the most reliable early diagnostic tool, capable of detecting the virus up to seven days after symptom onset. Combined NS1 and antibody-based assays provide improved diagnostic accuracy, making them practical approaches in suspected dengue cases, especially in endemic regions where dengue should be considered in all patients presenting with acute undifferentiated fever.

As no specific antiviral treatment for dengue is currently available, management primarily relies on supportive care, particularly careful fluid replacement and close clinical monitoring. Early recognition of warning signs such as plasma leakage, bleeding, shock, and organ dysfunction is essential to reduce morbidity and mortality. Mild cases without warning signs can often be managed with oral hydration and fever control, while severe cases require hospitalization, intravenous fluids, and intensive monitoring of vital signs, hematocrit, and urine output. Patients with dengue hemorrhagic fever (DHF) or dengue shock syndrome (DSS) may require rapid fluid resuscitation using crystalloids or colloids, blood transfusions for severe bleeding, and management of metabolic complications. Unnecessary invasive procedures and prophylactic platelet transfusions should be avoided due to bleeding risks. Comorbid conditions may worsen disease severity, and there is currently no proven benefit of therapies such as corticosteroids, chloroquine, or immunoglobulins. With timely supportive treatment, most patients recover completely within a few days after the critical phase.

"Dengue Pipeline Insight 2026" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Dengue pipeline landscape is provided which includes the disease overview and Dengue treatment guidelines. The assessment part of the report embraces, in depth Dengue commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Dengue collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Dengue Pipeline Report Highlights

• • The companies and academics are working to assess challenges and seek opportunities that could influence Dengue R&D. The therapies under development are focused on novel approaches to treat/improve Dengue.

Dengue Emerging Drugs Analysis

This segment of the Dengue report encloses its detailed analysis of various drugs in different stages of clinical development, including Phase III, II, I, Preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Dengue Emerging Drugs

V181: Merck Sharp & Dohme LLC

V181 is an investigational quadrivalent dengue vaccine candidate developed by Merck & Co., aimed at providing immunity against dengue fever, a mosquito-borne viral infection that poses significant health risks worldwide, particularly in tropical and subtropical regions. V181 is designed to be a single-dose vaccination and is being studied in individuals to provide protection against dengue, including severe forms, whether the individuals have been previously infected with the dengue virus or had no prior infections. Early studies suggest that V181 elicits a broad and balanced immune response across all dengue virus types, aiming to provide comprehensive protection and potentially prevent severe outcomes like dengue hemorrhagic fever. Currently the drug is in Phase III stage of its development for the treatment of Dengue.

ISLA101: Isla Pharmaceuticals

ISLA-101 is the lead antiviral drug candidate being developed by Island Pharmaceuticals for the prevention and treatment of dengue fever and other mosquito-borne viral diseases such as Zika, West Nile, and Yellow Fever. Originally developed for cancer and respiratory conditions, the drug underwent 48 Phase I and II clinical trials and demonstrated a strong safety profile in humans, allowing it to be repurposed for antiviral use. ISLA-101 works by blocking the entry of a key viral protein into the host cell nucleus, thereby preventing viral replication. Preclinical studies conducted by Monash University and Harvard University showed promising antiviral activity against dengue and Zika viruses in animal models. The drug is currently advancing through Phase II clinical trials, with early results indicating favorable safety and potential anti-dengue activity. ISLA-101 is being developed as an oral formulation, with additional exploration into long-acting and intravenous formulations for severe dengue cases.

EMX-001: Glyden Pharma

EMX-001 is an investigational peptide-based vaccine candidate being developed by Emergex Vaccines for the prevention of dengue and other flaviviral infections, including Zika and yellow fever. It uses a synthetic nanoparticle platform designed to stimulate a strong T-cell immune response rather than relying primarily on antibody production, which may help reduce the risk of antibody-dependent enhancement (ADE) associated with dengue. EMX-001 incorporates dengue-specific peptides delivered through gold nanoparticles and is being explored as a microneedle patch vaccine for easier administration and improved stability. The candidate has completed Phase I clinical evaluation in healthy adults, where it was assessed for safety, tolerability, and immune response generation.

CDX DENV: Codagenix

CDX-DENV (also referred to as CodaVax-DENV) is an investigational tetravalent live-attenuated dengue vaccine candidate being developed by Codagenix using its proprietary synthetic biology and codon deoptimization platform. The vaccine is designed to provide balanced immunity against all four dengue virus serotypes (DENV-1 to DENV-4), addressing a major challenge in dengue vaccine development where incomplete immunity may increase the risk of antibody-dependent enhancement (ADE). Unlike conventional dengue vaccines based on older viral strains, CDX-DENV is engineered from contemporary circulating dengue strains to improve safety and immune protection. Preclinical studies demonstrated that the vaccine is safe and immunogenic in non-human primates, producing a balanced immune response across all serotypes. The program is currently in the preclinical-to-early clinical development stage, supported by multiple funding awards from the U.S. Department of Defense to advance manufacturing, IND-enabling studies, and Phase I clinical evaluation.
 Further product details are provided in the report……..

Dengue Drug Therapeutic Assessment

This segment of the report provides insights about the different Dengue drugs segregated based on following parameters that define the scope of the report, such as:

Major Dengue Players in Dengue  

• • There are approx. 15+ key companies which are developing the therapies for Dengue. The companies which have their Dengue drug candidates in the most advanced stage, i.e. Phase II include, NeuroRx.

Dengue Clinical Trial Phases

• DelveInsight’s report covers around 20+ products under different phases of clinical development like
  
  • • Late stage products (Phase III)
  • • Mid-stage products (Phase II)
  • • Early-stage product (Phase I) along with the details of 
  • • Pre-clinical and Discovery stage candidates
  • • Discontinued & Inactive candidates

Dengue Drug Route of Administration

• Dengue pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as 
• • • Oral
  • • Intravenous
  • • Subcutaneous
  • • Parenteral 
  • • Topical

Dengue Product Molecule Type

• Products have been categorized under various Molecule types such as
• • • Recombinant fusion proteins
  • • Small molecule
  • • Monoclonal antibody
  • • Peptide
  • • Polymer 
  • • Gene therapy

Dengue Product Type

• Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Dengue Clinical Trial Activities

The Dengue Pipeline report provides insights into Dengue Clinical Trials within Phase III, II, I, preclinical and discovery stage. It also analyses Dengue therapeutic drugs key players involved in developing key drugs. 

Dengue Pipeline Development Activities

The Dengue Clinical Trial analysis report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Dengue drugs.

Dengue Pipeline Report Insights

• • Dengue Pipeline Analysis
• • Therapeutic Assessment
• • Unmet Needs
• • Impact of Drugs

Dengue Pipeline Report Assessment

• • Pipeline Product Profiles
• • Therapeutic Assessment
• • Pipeline Assessment
• • Inactive drugs assessment
• • Unmet Needs

Key Questions Answered In The Dengue Pipeline Report

Current Treatment Scenario and Emerging Therapies:

• • How many companies are developing Dengue drugs?
• • How many Dengue drugs are developed by each company?
• • How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Dengue?
• • What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Dengue therapeutics? 
• • What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies? 
• • What are the clinical studies going on for Dengue and their status?
• • What are the key designations that have been granted to the emerging drugs?

Dengue Key Companies

• • Merck Sharp & Dohme LLC
• • Island Pharmaceuticals
• • Novartis Pharmaceuticals
• • AbViro
• • Glyden Pharma
• • Codagenix
• • 60 Degree Pharmaceutical
• • Meiji Holdings
• • Calibr- Skaggs
• • Chugai Pharmaceutical Co., Ltd.
• • GSK
• • Hyundai Bioscience
• • CLAYTON BIOTECHNOLOGIES

Dengue Key Products

• • V181
• • ISLA101
• • EYU688
• • AV-1
• • EMX-001
• • CDX DENV
• • Celgosivir
• • KD-382
• • Research Program: Dengue Virus
• • AID351
• • Xafty
• • Vacunax